TREM2 Agonist Therapy for Neurodegeneration

TREM2 Agonist Therapy for Neurodegeneration

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">TREM2 Agonist Therapy for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Trial</td>
<td>Phase</td>
</tr>
<tr>
<td class="label">INVOKE-2</td>
<td>Phase 2</td>
</tr>
<tr>
<td class="label">Phase 1</td>
<td>Phase 1</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Company</td>
</tr>
<tr>
<td class="label">AL002</td>
<td>Alector/AbbVie</td>
</tr>
<tr>
<td class="label">AL003</td>
<td>Alector</td>
</tr>
<tr>
<td class="label">HL-85</td>
<td>H3 Biomedicine/Eisai</td>
</tr>
<tr>
<td class="label">H3B-10252</td>
<td>H3 Biomedicine</td>
</tr>
</table>

TREM2 agonist therapy represents a breakthrough immunomodulatory approach targeting the [Triggering Receptor Expressed on Myeloid Cells 2](/proteins/trem2) (TREM2) pathway to enhance microglial function across multiple neurodegenerative diseases. TREM2 is a cell surface receptor primarily expressed on [microglia](/cell-types/microglia-neuroinflammation) in the central nervous system and plays a critical role in modulating the brain's innate immune response. [@trem2020]

TREM2 Agonist Therapy for Neurodegeneration

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">TREM2 Agonist Therapy for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Trial</td>
<td>Phase</td>
</tr>
<tr>
<td class="label">INVOKE-2</td>
<td>Phase 2</td>
</tr>
<tr>
<td class="label">Phase 1</td>
<td>Phase 1</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Company</td>
</tr>
<tr>
<td class="label">AL002</td>
<td>Alector/AbbVie</td>
</tr>
<tr>
<td class="label">AL003</td>
<td>Alector</td>
</tr>
<tr>
<td class="label">HL-85</td>
<td>H3 Biomedicine/Eisai</td>
</tr>
<tr>
<td class="label">H3B-10252</td>
<td>H3 Biomedicine</td>
</tr>
</table>

TREM2 agonist therapy represents a breakthrough immunomodulatory approach targeting the [Triggering Receptor Expressed on Myeloid Cells 2](/proteins/trem2) (TREM2) pathway to enhance microglial function across multiple neurodegenerative diseases. TREM2 is a cell surface receptor primarily expressed on [microglia](/cell-types/microglia-neuroinflammation) in the central nervous system and plays a critical role in modulating the brain's innate immune response. [@trem2020]

Loss-of-function variants in the TREM2 gene (such as R47H, R62H, R47H) significantly increase risk for [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), [amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis), and [frontotemporal dementia](/diseases/frontotemporal-dementia), making TREM2 activation a promising therapeutic strategy across these conditions. [@trem2022]

Mechanism of Action

TREM2 is a cell surface receptor on microglia that recognizes multiple ligands including [amyloid-beta](/proteins/amyloid-beta) plaques, lipid particles, [apolipoprotein E](/proteins/apoe) (apoE), and cellular debris. Upon ligand binding, TREM2 signals through the adaptor protein TYROBP (DAP12) to activate downstream pathways including PI3K/Akt, MAPK/ERK, and SYK kinase. This signaling drives critical microglial functions: [@trem2021]

• Phagocytosis: TREM2 activation enhances microglial clearance of pathological protein aggregates and cellular debris
• Metabolic reprogramming: TREM2 signaling supports the inflammatory metabolic state of disease-associated microglia (DAM)
• Survival signaling: TREM2 provides pro-survival signals that prevent microglial [apoptosis](/entities/apoptosis)
• Clustering: TREM2 promotes microglial clustering around pathological lesions, forming a protective barrier

Clinical Candidates

AL002 (Alector/AbbVie)

AL002 is a monoclonal antibody designed to activate TREM2 by binding to a distinct epitope that promotes receptor clustering and signaling. It represents the most advanced TREM2-targeting antibody in clinical development.

• Mechanism: Agonist antibody binding to extracellular domain of TREM2
• Company: Alector (developed with AbbVie)
• Phase: Phase 2 (INVOKE-2 trial)
• Indications: [Alzheimer's disease](/diseases/alzheimers-disease)

Clinical Trial Status

Phase 1 Results

The Phase 1 study demonstrated:

• Dose-dependent engagement of TREM2
• Acceptable safety profile in healthy volunteers and AD patients
• Increased CSF sTREM2 levels indicating target engagement
• No serious treatment-related adverse events [@phase2024]

HL-85 (H3 Biomedicine/Eisai)

HL-85 (also known as H3B-10252) is a TREM2-targeting monoclonal antibody being developed by H3 Biomedicine (a subsidiary of Eisai) for neurodegenerative diseases.

• Mechanism: Agonist antibody targeting TREM2 to enhance microglial function
• Company: H3 Biomedicine (Eisai)
• Preclinical/Phase 1: Early-stage development
• Indications: [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease)

Development Status

HL-85 represents Eisai's entry into the TREM2 agonist space, leveraging their experience with [lecanemab](/entities/lecanemab) and other Alzheimer's therapeutics. The program aims to develop a TREM2 agonist with optimal brain penetration and dosing. [@eisai2024]

Other Pipeline Agents

Evidence by Disease

Alzheimer's Disease (AD)

TREM2 agonists have the strongest clinical evidence in Alzheimer's disease, where microglial dysfunction plays a central role in disease progression.

Genetic Rationale

• TREM2 R47H variant: 3-4x increased AD risk; impairs ligand binding
• TREM2 R62H variant: ~2x increased AD risk; partial loss of function
• TREM2 loss-of-function: Reduces microglial phagocytosis of amyloid

Clinical Evidence

• AL002 Phase 1 showed dose-dependent TREM2 engagement
• CSF sTREM2 elevation correlates with treatment response
• Amyloid plaque clearance observed in preclinical models
• INVOKE-2 trial evaluating clinical efficacy endpoints [@invoke]

Biomarker Endpoints

• Amyloid PET (Centiloid reduction)
• CSF biomarkers (p-tau181, total tau, Aβ42/40)
• CSF sTREM2 (target engagement marker)
• MRI volumetric measures

Parkinson's Disease (PD)

TREM2 is implicated in [Parkinson's disease](/diseases/parkinsons-disease) through its role in clearing [alpha-synuclein](/proteins/alpha-synuclein) aggregates and regulating neuroinflammation.

Genetic Rationale

• TREM2 variants associated with PD risk
• Reduced TREM2 function may impair alpha-synuclein clearance
• Neuroinflammation drives PD progression

Clinical Development

• HL-85 being evaluated for PD indication
• Preclinical data supports alpha-synuclein clearance
• Phase 1/2 trials anticipated

Corticobasal Syndrome (CBS)

[Corticobasal syndrome](/diseases/corticobasal-syndrome) involves tau pathology and benefits from microglial modulation.

Rationale

• TREM2 activation may enhance tau clearance
• Neuroinflammation contributes to CBS progression
• Microglial clustering around tau lesions

Clinical Status

• No current TREM2 trials in CBS
• Potential indication for future development

Progressive Supranuclear Palsy (PSP)

[Progressive supranuclear palsy](/diseases/progressive-supranuclear-palsy) is a tauopathy that may benefit from TREM2 agonism.

Rationale

• Tau pathology triggers microglial activation
• TREM2 may help clear tau aggregates
• Neuroinflammation drives disease progression

Clinical Status

• No current TREM2 trials in PSP
• Scientific rationale supports investigation

Amyotrophic Lateral Sclerosis (ALS)

[Amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis) involves motor neuron degeneration with microglial involvement.

Genetic Rationale

• TREM2 variants associated with ALS risk
• Microglial dysfunction contributes to motor neuron damage
• Enhanced microglial function may slow progression

Clinical Status

• No current TREM2 trials in ALS
• Preclinical models show promise

Frontotemporal Dementia (FTD)

[Frontotemporal dementia](/diseases/frontotemporal-dementia) involves protein aggregates and neuroinflammation.

Genetic Rationale

• TREM2 variants linked to FTD risk
• Microglial activation in FTD pathology
• Protein aggregate clearance role

Clinical Status

• No current TREM2 trials in FTD
• Potential future indication

Huntington's Disease

[Huntington's disease](/diseases/huntingtons) involves mutant huntingtin protein aggregation and microglial activation.

Rationale

• TREM2 may enhance mutant huntingtin clearance
• Neuroinflammation contributes to progression
• Microglial modulation potential therapeutic approach

Clinical Status

• No current TREM2 trials in HD
• Preclinical rationale exists

Biomarkers and Patient Selection

CSF sTREM2

Soluble TREM2 (sTREM2) in cerebrospinal fluid reflects TREM2 shedding and microglial activation.

• Baseline sTREM2: May predict response to TREM2 agonists
• Dynamic changes: Treatment-induced sTREM2 increase indicates target engagement
• Correlation: Higher sTREM2 in early disease stages

Genetic Stratification

Patients with TREM2 risk variants may particularly benefit from TREM2 agonism:

• R47H carriers: ~3-4x increased AD risk; reduced ligand binding
• R62H carriers: Intermediate risk; partial loss of function
• R47H homozygotes: Very high risk; may benefit most from therapy

Proteinopathy Status

TREM2 agonists require the presence of pathological protein aggregates as ligands:

• Amyloid-positive: Required for AD trials
• Alpha-synucleinpositive: Target for PD trials
• Tau-positive: Important for all tauopathies

Safety Considerations

Expected ARIA

Similar to other antibody therapies targeting immune pathways:

• ARIA-E: Amyloid-related imaging abnormalities - edema; monitoring required
• ARIA-H: Microhemorrhages; less common than with amyloid antibodies

Immune-Related Adverse Events

• Injection site reactions (for subcutaneous formulations)
• Flu-like symptoms
• Potential for enhanced infection risk

Monitoring Requirements

• MRI at baseline and during treatment
• Regular neurological assessments
• CSF sampling for biomarker monitoring

Future Directions

Combination Approaches

TREM2 agonists may be combined with:

• [Amyloid-targeting antibodies](/therapeutics/amyloid-immunotherapies) (lecanemab, donanemab)
• [Tau-targeting therapies](/therapeutics/tau-immunotherapies-neurodegeneration)
• [Anti-inflammatory agents](/therapeutics/neuroinflammation-modulation-therapies)

Next-Generation Agents

• Small molecule TREM2 agonists
• Gene therapy approaches
• Engineered bispecific antibodies

Cross-Linking

• TREM2 Gene
• [Microglia](/cell-types/microglia)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• Amyloid Immunotherapies
• Tau Immunotherapies
• Neuroinflammation Modulation
• Microglial Modulation Therapy
• [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
• [Frontotemporal Dementia](/diseases/frontotemporal-dementia)
• Progressive Supranuclear Palsy
• Corticobasal Syndrome
• [Huntington's Disease](/diseases/huntingtons)

References

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: SIRT1
• [CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
• [Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: HCRTR1/HCRTR2
• [Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1
• [Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: ABCA1/LDLR/SREBF2
• [Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: NLRP3, CASP1, IL1B, PYCARD
• [Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — <span style="color:#81c784;font-weight:600">0.75</span> · Target: TFRC
• [Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — <span style="color:#81c784;font-weight:600">0.74</span> · Target: P2RY1 and P2RX7

• [TREM2 agonism vs antagonism in DAM microglia](/analysis/SDA-2026-04-01-gap-001) &#x1f504;
• [TREM2 agonism vs antagonism in DAM microglia](/analysis/SDA-2026-04-02-gap-001) &#x1f504;
• [Immune atlas neuroinflammation analysis in neurodegeneration](/analysis/SDA-2026-04-02-gap-immune-atlas-neuroinflam-20260402) &#x1f504;
• [Selective vulnerability of entorhinal cortex layer II neurons in AD](/analysis/SDA-2026-04-01-gap-004) &#x1f504;
• [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) &#x1f504;